CDK4 and neoplasm: Based on this logic, combining a HIF2 inhibitor with a CDK4/6 inhibitor should be additive or synergistic, at least in ccRCCs that are intrinsically HIF2-dependent, leading to deeper and more frequent tumor regressions.